Dr Reddys Laboratories Ltd Share Price – NSE /  BSE

Pharmaceuticals, Mid Cap

Dr Reddys Laboratories Ltd is up for a third straight session today. The stock is quoting at Rs 1364.9, up 1.02% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.28% on the day, quoting at 25069.95. The Sensex is at 82276.06, down 0.29%. Dr Reddys Laboratories Ltd has gained around 13.07% in last one month.

Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has gained around 4.05% in last one month and is currently quoting at 22057.15, up 0.76% on the day. The volume in the stock stood at 11.71 lakh shares today, compared to the daily average of 17.74 lakh shares in last one month.

The benchmark June futures contract for the stock is quoting at Rs 1361.1, up 0.71% on the day. Dr Reddys Laboratories Ltd is up 11.95% in last one year as compared to a 7.14% jump in NIFTY and a 12.03% jump in the Nifty Pharma index.

The PE of the stock is 21.07 based on TTM earnings ending March 25.

Powered by Capital Market - Live News

Dr Reddys Laboratories Ltd gained for a fifth straight session today. The stock is quoting at Rs 1321.8, up 0.07% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.46% on the day, quoting at 25117.25. The Sensex is at 82511.15, up 0.39%. Dr Reddys Laboratories Ltd has risen around 10.56% in last one month.

Meanwhile, Nifty Pharma index of which Dr Reddys Laboratories Ltd is a constituent, has risen around 3.24% in last one month and is currently quoting at 21684.4, up 0.47% on the day. The volume in the stock stood at 9.1 lakh shares today, compared to the daily average of 19.37 lakh shares in last one month.

The benchmark June futures contract for the stock is quoting at Rs 1320.2, up 0.24% on the day. Dr Reddys Laboratories Ltd is up 8.24% in last one year as compared to a 7.99% spurt in NIFTY and a 10.18% spurt in the Nifty Pharma index.

The PE of the stock is 20.6 based on TTM earnings ending March 25.

Powered by Capital Market - Live News

Keytruda, a widely used immunotherapy for various cancer types, recorded global sales of $29.5 billion in 2024. The partnership involves joint development and manufacturing of the biosimilar, with both companies sharing costs and responsibilities. Subject to certain conditions, both parties will also have rights to commercialize the product worldwide.

Alvotech, a biotech company focused on biosimilars, already has two approved biosimilars, adalimumab and ustekinumab, marketed in several countries. It has a strong pipeline of nine additional biosimilars and a global network of commercial partnerships spanning the US, Europe, Asia, Latin America, and Africa.

Dr. Reddy's Laboratories is a global pharmaceutical company. It offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC.

On a consolidated basis, net profit of Dr Reddy's Laboratories rose 21.64% to Rs 1593.30 crore while net sales rose 20.09% to Rs 8506 crore in Q4 March 2025 over Q4 March 2024.

Powered by Capital Market - Live News

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide (Alvotech), and Dr. Reddy's Laboratories announced that the companies have entered into a collaboration and license agreement to co develop, manufacture and commercialize a biosimilar candidate to Keytruda? (pembrolizumab) for global markets.

Keytruda? (pembrolizumab) is indicated for the treatment of numerous cancer types.

In 2024, worldwide sales of Keytruda were US$29.5 billion [1]. The collaboration combines Dr. Reddy's and Alvotech's proven capabilities in biosimilars, thereby, speeding up the development process and extending the global reach for this biosimilar candidate.

Under the terms of the agreement, the parties will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities. Subject to certain exceptions, each party will have the right to commercialize the product globally.

Powered by Capital Market - Live News